Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World

Executive Summary

Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.

You may also be interested in...



Vaccines Unit Shines For GSK In 3Q

GlaxoSmithKline's vaccine's business, which has been under the spotlight this week following a US regulatory submission for its highly anticipated shingles vaccines, Shingrix, has come out shining in the third quarter – setting the stage for a strong full-year readout.

Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back

Pfizer commits to “late November” launch for its biosimilar version of infliximab, partnered with Celltrion, which will be the second biosimilar to reach the US market. Remicade innovator Janssen considers it an “at risk” launch and will continue patent litigation, as well as commercial tactics to protect its market.

Mylan Confident On Advair Generic First-Round Approval

President Rajiv Malik said there has been “huge movement” at the agency around executing on the first ANDA for a generic version of GlaxoSmithKline’s blockbuster Advair.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel